Conscience has published its latest Annual Report, highlighting a year of progress in advancing open science drug discovery and building the foundations for long-term impact across the research and innovation ecosystem.
In 2025, Conscience moved from concept to execution, funding the first projects through the Developing Medicines through Open Science (DMOS) program, expanding the CACHE Challenges, and launching new advisory services to support the implementation of open science approaches. The organization also contributed to the development of BEACON, a new consortium focused on strengthening benchmarking and critical assessment as core scientific infrastructure.
The report reflects growing engagement from researchers, companies, and partners across the global community, and outlines Conscience’s focus on scaling its programs, deepening partnerships, and advancing drug development through open science.
